Consumer & Travel Stock News
Friday, August 28, 2026
Roivant Announces FDA Approval for LISRAYA™, a New Dermatomyositis Treatment
Roivant Sciences announced that the U.S. Food and Drug Administration (FDA) has approved LISRAYA™ (brepocitinib) for the treatment of adults with...
🟢 Webus International is trading 23.48% up in after-hours trading following a $75 million at-the-market offering filing
Webus International is trading at $14.20 (+23.48%) after its August 26 SEC filing for an at-the-market offering of up to $75 million through Rodman &...
Nike Taps Walmart Veteran for Turnaround, Stock Hits 12-Year Low
Nike appointed Jane Ewing as Executive Vice President and Chief Commercial Officer, effective September 7. Ewing joins from Walmart with over two decades of...
Roivant Secures FDA Approval for First Targeted Dermatomyositis Therapy
The U.S. Food and Drug Administration (FDA) approved LISRAYA (brepocitinib) for adults with dermatomyositis. Roivant Sciences' subsidiary, Priovant...
Pfizer Secures FDA Approval for 2026-2027 COVID Shot, Targeting XFG Variant
Anthropic Launches Hardware Standard, Automating Scientific Research and Manufacturing
Disney Announces 'Toy Story 5' Disney+ Release Date and New Walt Disney World Resort Details
Outlook Therapeutics Appoints Kevin Lundquist as New CFO, Succeeding Lawrence Kenyon
Other News
Christopher Bloomstran's Semper Augustus Cuts Five Below Stake by 45%
Jensen Investment Management Boosts Stake in TJX by Over 2000%
Air New Zealand reports $336 million loss, trailing profitable global rivals
Icahn Group Representatives Resign from JetBlue Board as Ownership Stake Decreases
Femasys partners with UNC Health, offering fertility treatments without specialist referrals
H.C. Wainwright Reaffirms 'Buy' Rating for Gossamer Bio Amid NDA Progress for Seralutinib
Boot Barn Announces Stockholder Approval of 2026 Equity Incentive Plan
Roivant's Brepocitinib Clears Skin in Phase 3, Targeting 2026 FDA Approval
Johnson & Johnson's Psoriasis Pill Icotyde Gains Approval in China
BioXcel's Earnings Crater Raises a Brutal Question: Can a Sub-Dollar Biotech Survive Its Own Cash Burn?
Sphera Funds Management Discloses 5.33% Stake in Tenax Therapeutics
CalciMedica's Reverse Stock Split Buys Time on Nasdaq, but Can a Sub-Dollar Biotech Survive the Signal It Sends?
CalciMedica Announces 1-for-5 Reverse Stock Split and Reduction of Authorized Shares
Alibaba Bets $10 Billion of New Stock on an AI Future — But Can Cloud Growth Outrun the Dilution?
Sellas Stock Jumps 7% on Unverified Leukemia Trial Milestone — But Can Investors Trust a Rumor With This Much at Stake?
US Waives Tariffs on Beef Imports to Cut Prices